ClinicaliQ Trial Snapshot
- A Study of AZD0120 in Autoimmune Diseases — Recruiting • Phase I • Neurology • NCT07295847.
- What is being tested: AZD0120, a dual-targeting CAR+ T-cell therapy that simultaneously targets BCMA and CD19, is being evaluated for safety and tolerability in a Phase 1b study across three difficult-to-treat autoimmune conditions (systemic sclerosis, idiopathic inflammatory myopathies, and rheumatoid arthritis).
- Patient eligibility overview: The trial recruits adult participants with confirmed diagnoses of systemic sclerosis, idiopathic inflammatory myopathies, or difficult-to-treat rheumatoid arthritis, representing patient populations with limited current therapeutic options.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This trial is a Phase 1b, open-label, multi-center, clinical study of AZD0120, a BCMA/CD19 dual targeting CAR+ T-cell therapy, to evaluate the safety and tolerability in adult participants with systemic sclerosis (SSc), idiopathic inflammatory myopathies (IIM), or difficult-to-treat rheumatoid arthritis (D2T RA).
Eligibility Snapshot
- : * Capable of giving signed informed consent. * Adequate physiological function and reserve at screening. * Able to comply with recommended medication washout period. * Participants who are suitable for the study as determined by medical evaluation and at the discretion of the investigator. * Willingness to remain on/start appropriate, highly effective methods of birth control or other acceptable criteria.
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.